Menu
ETF
Annual · values202520242023202220212020
Operating Cash Flow-170.87 M USD13.55 M USD-59.27 M USD-40.08 M USD-66.76 M USD-31.20 M USD
Depreciation & Amortization1.37 M USD100000 USD100000 USD319000 USD213000 USD637000 USD
Stock-Based Compensation22.09 M USD14.53 M USD9.23 M USD5.84 M USD19.19 M USD2.64 M USD
Capital Expenditures339000 USD563000 USD175000 USD199000 USD1.37 M USD917000 USD
Cash Flow from Investing56.77 M USD-106.10 M USD-87.18 M USD-199000 USD-66.48 M USD-917000 USD
Cash Flow from Financing104.60 M USD72.40 M USD6.90 M USD190.73 M USD614000 USD408.51 M USD
Dividends Paid
Stock Buybacks
Free Cash Flow-171.21 M USD12.98 M USD-59.44 M USD-40.28 M USD-68.13 M USD-32.11 M USD

Ars Pharmaceuticals Inc. specializes in the biopharmaceutical sector, focusing on the development of innovative, self-administered therapeutics aimed at improving patient outcomes. The company's primary purpose is to advance medical solutions for allergy-related indications, enhancing safety and convenience for patients affected by conditions such as allergic reactions requiring rapid intervention. Notable for its emphasis on creating user-friendly delivery mechanisms, Ars Pharmaceuticals tailors its offerings to both patients and healthcare professionals seeking reliable and effective emergency treatments. By addressing critical needs within the healthcare industry, Ars Pharmaceuticals plays a significant role in expanding options in allergy treatment and management. Its contributions to the medical field underscore its ongoing commitment to transforming therapeutic landscapes and meeting pressing health challenges.